Is ATyr Pharma, Stock a Good Investment?
ATyr Pharma, Investment Advice | ATYR |
- Examine ATyr Pharma,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ATyr Pharma,'s leadership team and their track record. Good management can help ATyr Pharma, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact ATyr Pharma,'s business and its evolving consumer preferences.
- Compare ATyr Pharma,'s performance and market position to its competitors. Analyze how ATyr Pharma, is positioned in terms of product offerings, innovation, and market share.
- Check if ATyr Pharma, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ATyr Pharma,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in aTyr Pharma, stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if aTyr Pharma, is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Ignores market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine ATyr Pharma, Stock
Researching ATyr Pharma,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 64.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. aTyr Pharma, recorded a loss per share of 0.9. The entity had not issued any dividends in recent years. The firm had 1:14 split on the 1st of July 2019.
To determine if ATyr Pharma, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ATyr Pharma,'s research are outlined below:
| aTyr Pharma, had very high historical volatility over the last 90 days | |
| aTyr Pharma, has a very high chance of going through financial distress in the upcoming years | |
| aTyr Pharma, was previously known as LIFE Old and was traded on NASDAQ Exchange under the symbol LIFE. | |
| The company reported the previous year's revenue of 235 K. Net Loss for the year was (64.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ATyr Pharma, generates negative cash flow from operations | |
| About 64.0% of the company shares are held by institutions such as insurance companies |
ATyr Pharma,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 144.01 M.Basic technical analysis of ATyr Stock
As of the 21st of March, ATyr Pharma, shows the Coefficient Of Variation of 1694.58, downside deviation of 5.56, and Risk Adjusted Performance of 0.0608. aTyr Pharma, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm aTyr Pharma, mean deviation, information ratio, as well as the relationship between the Information Ratio and expected short fall to decide if aTyr Pharma, is priced correctly, providing market reflects its regular price of 3.68 per share. Given that ATyr Pharma, has maximum drawdown of 28.8, we suggest you to validate aTyr Pharma,'s prevailing market performance to make sure the company can sustain itself at a future point.ATyr Pharma,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ATyr Pharma, insiders, such as employees or executives, is commonly permitted as long as it does not rely on ATyr Pharma,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ATyr Pharma, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Denyes Nancy over a month ago Disposition of 899 shares by Denyes Nancy of ATyr Pharma, at 3.78 subject to Rule 16b-3 | ||
Denyes Nancy over two months ago Acquisition by Denyes Nancy of 275000 shares of ATyr Pharma, at 3.74 subject to Rule 16b-3 | ||
Schimmel Paul over six months ago Acquisition by Schimmel Paul of 52300 shares of ATyr Pharma, at 1.9319 subject to Rule 16b-3 |
ATyr Pharma,'s Outstanding Corporate Bonds
ATyr Pharma, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. aTyr Pharma, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ATyr bonds can be classified according to their maturity, which is the date when aTyr Pharma, has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| APTV 415 01 MAY 52 Corp BondUS00217GAC78 | View | |
| APTV 325 01 MAR 32 Corp BondUS00217GAB95 | View | |
| ASBBNK 1625 22 OCT 26 Corp BondUS00216LAD55 | View | |
| ASBBNK 5398 29 NOV 27 Corp BondUS00216LAF04 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand ATyr Pharma,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ATyr Pharma,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0608 | |||
| Mean Deviation | 4.31 | |||
| Semi Deviation | 5.08 | |||
| Downside Deviation | 5.56 | |||
| Coefficient Of Variation | 1694.58 | |||
| Standard Deviation | 5.91 | |||
| Variance | 34.98 | |||
| Information Ratio | 0.0695 | |||
| Total Risk Alpha | 0.8214 | |||
| Sortino Ratio | 0.0741 | |||
| Maximum Drawdown | 28.8 | |||
| Value At Risk | (8.18) | |||
| Potential Upside | 11.14 | |||
| Downside Variance | 30.86 | |||
| Semi Variance | 25.82 | |||
| Expected Short fall | (5.32) | |||
| Skewness | 0.1639 | |||
| Kurtosis | 0.9224 |
| Risk Adjusted Performance | 0.0608 | |||
| Mean Deviation | 4.31 | |||
| Semi Deviation | 5.08 | |||
| Downside Deviation | 5.56 | |||
| Coefficient Of Variation | 1694.58 | |||
| Standard Deviation | 5.91 | |||
| Variance | 34.98 | |||
| Information Ratio | 0.0695 | |||
| Total Risk Alpha | 0.8214 | |||
| Sortino Ratio | 0.0741 | |||
| Maximum Drawdown | 28.8 | |||
| Value At Risk | (8.18) | |||
| Potential Upside | 11.14 | |||
| Downside Variance | 30.86 | |||
| Semi Variance | 25.82 | |||
| Expected Short fall | (5.32) | |||
| Skewness | 0.1639 | |||
| Kurtosis | 0.9224 |
Consider ATyr Pharma,'s intraday indicators
ATyr Pharma, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ATyr Pharma, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ATyr Pharma, time-series forecasting models is one of many ATyr Pharma,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ATyr Pharma,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ATyr Stock media impact
Far too much social signal, news, headlines, and media speculation about ATyr Pharma, that are available to investors today. That information is available publicly through ATyr media outlets and privately through word of mouth or via ATyr internal channels. However, regardless of the origin, that massive amount of ATyr data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ATyr Pharma, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ATyr Pharma, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ATyr Pharma,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ATyr Pharma, alpha.
ATyr Pharma, Corporate Management
| Danielle Campbell | VP Resource | Profile | |
| Jill CPA | Chief Officer | Profile | |
| Jill Broadfoot | Chief Officer | Profile | |
| Jayant MBA | Vice Operations | Profile | |
| Peter Villiger | Vice Development | Profile | |
| Nancy Krueger | General Secretary | Profile |
Already Invested in aTyr Pharma,?
The danger of trading aTyr Pharma, is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ATyr Pharma, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ATyr Pharma,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile aTyr Pharma, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.